AU2013355039B2 - Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive Tat derivative polypeptides - Google Patents

Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive Tat derivative polypeptides Download PDF

Info

Publication number
AU2013355039B2
AU2013355039B2 AU2013355039A AU2013355039A AU2013355039B2 AU 2013355039 B2 AU2013355039 B2 AU 2013355039B2 AU 2013355039 A AU2013355039 A AU 2013355039A AU 2013355039 A AU2013355039 A AU 2013355039A AU 2013355039 B2 AU2013355039 B2 AU 2013355039B2
Authority
AU
Australia
Prior art keywords
disease
immunosuppressive
tat
tat derivative
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013355039A
Other languages
English (en)
Other versions
AU2013355039A1 (en
Inventor
Colin BIER
Joshua Goldberg
Sophie HANSCOM
Christoph HOTZ-BEHOFSITS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resilion Pharmaceuticals LLC
Original Assignee
Resilion Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resilion Pharmaceuticals LLC filed Critical Resilion Pharmaceuticals LLC
Publication of AU2013355039A1 publication Critical patent/AU2013355039A1/en
Application granted granted Critical
Publication of AU2013355039B2 publication Critical patent/AU2013355039B2/en
Assigned to RESILION PHARMACEUTICALS, LLC reassignment RESILION PHARMACEUTICALS, LLC Request for Assignment Assignors: PIN PHARMA, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013355039A 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive Tat derivative polypeptides Active AU2013355039B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734135P 2012-12-06 2012-12-06
US61/734,135 2012-12-06
US201361881266P 2013-09-23 2013-09-23
US61/881,266 2013-09-23
PCT/US2013/073658 WO2014089480A1 (en) 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Publications (2)

Publication Number Publication Date
AU2013355039A1 AU2013355039A1 (en) 2015-07-02
AU2013355039B2 true AU2013355039B2 (en) 2017-08-24

Family

ID=50884040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013355039A Active AU2013355039B2 (en) 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive Tat derivative polypeptides

Country Status (13)

Country Link
US (3) US9878001B2 (enExample)
EP (1) EP2928910B1 (enExample)
JP (2) JP6607784B2 (enExample)
CN (1) CN104981479B (enExample)
AU (1) AU2013355039B2 (enExample)
CA (1) CA2894166A1 (enExample)
DK (1) DK2928910T3 (enExample)
ES (1) ES2748423T3 (enExample)
IL (1) IL239271B (enExample)
NZ (1) NZ708836A (enExample)
RU (1) RU2653754C2 (enExample)
WO (1) WO2014089480A1 (enExample)
ZA (1) ZA201504100B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051245A1 (en) * 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
CN110290799A (zh) 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
BR112023003865A2 (pt) * 2020-09-04 2024-03-12 Dompe Farm Spa Peptídeos dotados de atividade angiogênica
EP3964225A1 (en) * 2020-09-04 2022-03-09 Dompe' Farmaceutici S.P.A. Peptides endowed with angiogenic activity
US20230364112A1 (en) * 2020-09-29 2023-11-16 Alps Biotech Co., Ltd. Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
WO2023062451A1 (en) * 2022-08-28 2023-04-20 Farhadi Andar Abi Ali Pegylated tat-efsevin-ta as an antiarrhythmic agent with favorable effect on heart failure caused by arrhythmia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009336A1 (en) * 2009-03-23 2011-01-13 Cohen David I Treatment of Cancers with Immunostimulatory HIV TAT Derivative Polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2792206B1 (fr) 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
ATE465754T1 (de) 1999-08-12 2010-05-15 Inist Inc Nicht-immunsuppresives hiv tat-protein
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20080044435A1 (en) 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AP2368A (en) 2001-05-03 2012-02-27 Fit Biotech Oyj Plc Novel expression vectors and uses thereof.
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
WO2015051245A1 (en) * 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009336A1 (en) * 2009-03-23 2011-01-13 Cohen David I Treatment of Cancers with Immunostimulatory HIV TAT Derivative Polypeptides

Also Published As

Publication number Publication date
EP2928910B1 (en) 2019-09-04
US20210069290A1 (en) 2021-03-11
CN104981479A (zh) 2015-10-14
US20140178420A1 (en) 2014-06-26
WO2014089480A1 (en) 2014-06-12
EP2928910A1 (en) 2015-10-14
CN104981479B (zh) 2021-06-01
NZ708836A (en) 2020-07-31
ZA201504100B (en) 2016-05-25
CA2894166A1 (en) 2014-06-12
EP2928910A4 (en) 2016-06-29
JP2016508121A (ja) 2016-03-17
IL239271A0 (en) 2015-07-30
AU2013355039A1 (en) 2015-07-02
IL239271B (en) 2019-09-26
ES2748423T3 (es) 2020-03-16
HK1216318A1 (en) 2016-11-04
RU2015126776A (ru) 2017-01-13
JP6607784B2 (ja) 2019-11-20
US20180185441A1 (en) 2018-07-05
US9878001B2 (en) 2018-01-30
JP2019163259A (ja) 2019-09-26
RU2653754C2 (ru) 2018-05-14
DK2928910T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
US20210069290A1 (en) Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides
JP2009525323A (ja) 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法
CN113855804A (zh) 用于治疗衰老相关病症的方法和组合物
US20200299328A1 (en) Polypeptide with function of inhibiting abeta 42 protein aggregation and use thereof, and gene encoding the polypeptide
AU2010283169B2 (en) Novel peptide and use thereof
JP2018525337A (ja) 軽度認知障害の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用
US20180170983A1 (en) New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
US11628206B2 (en) Method for inhibiting STAT3 activity comprising administering Ssu72
AU2020234373B9 (en) Novel peptide and use thereof
KR20090028624A (ko) 자가면역질환, 알러지성 질환 및 염증성 질환 치료용 약제 조성물 및 이의 전달 방법
HK1216318B (en) Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
EP1626984A1 (en) Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease
KR102684884B1 (ko) 신경줄기세포의 줄기세포능 증진을 위한 gng2의 용도
JP5967448B2 (ja) ２型ｔｎｆ受容体の発現を誘導する合成ペプチド及びその利用
CN102807609A (zh) 一种预防和/或治疗疼痛的多肽及其应用
Zhang et al. NgR acts as an inhibitor to axonal regeneration in adults
US10400027B2 (en) Protein and use thereof in treating multiple sclerosis
US20250154212A1 (en) Method of disrupting memory and lipopeptide for use in such method
US10125168B2 (en) Synthetic peptide for adjusting balance between presence of type 1 TNF receptor and type 2 TNF receptor and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: RESILION PHARMACEUTICALS, LLC

Free format text: FORMER OWNER(S): PIN PHARMA, INC.